Dan Stanton

BioProcess Insider is at Biotech Week Boston (BWB) to bring you the best from BPI East, Cell & Gene Therapy International, Well Characterized Biologics and more.

“Horrible” gene therapy launches, epitomized by BioMarin’s lackluster and limited rollout of Roctavian, are jeopardizing the sector, according to Dark Horse consultant Anthony Davies.

CDMO Resilience hosted visitors at its Boston manufacturing site during Biotech Week Boston.

Vertex says finding the sweet spot in manufacturing capacity is key to ensuring the successful rollout of sickle cell gene therapy Casgevy (exagamglogene autotemcel).

An Executive Order supporting homegrown biomanufacturing will remain in place whoever wins in November, says White House OSTP assistant director Sarah Glaven.

Vertex says finding the sweet spot in manufacturing capacity is key to ensuring the successful rollout of sickle cell gene therapy Casgevy (exagamglogene autotemcel).

Smaller innovators are more likely to be upended by US legislation aimed at restricting working with China-based CDMOs like WuXi Biologics, according to Latham Biopharm.

Cell therapies will play an increasingly important position in AstraZeneca’s broad oncology pipeline, an SVP told delegates at Biotech Week Boston (BWB) last month.

Diminished destocking and stabilized consumable demand are helping bioprocess vendors return to growth, but the slow recovery in funding remains a headwind.

Aurigene’s chief commercial officer says his firm and other Indian CDMOs are “a very viable alternative” if major Chinese manufacturers are removed from the US biopharma supply chain.